In the case of patients who have BRAF-driven mutations, on 17 August 2011, the U S Food and Drug Administration (FDA) approved a new drug, vemurafenib (PLX4032), a selective BRAF inhibitor (BRAFi) for the treatment of advanced metastatic melanoma [5,9,10]. Here, BRAF is linked to metastatic melanoma.